Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

Gastroenterology

Volumn 138, Issue 3, 2010, Pages 958-968

  Smith, J Joshua ^a,b   Deane, Natasha G ^a,c,d   Wu, Fei ^a   Merchant, Nipun B ^a,d   Zhang, Bing ^a   Jiang, Aixiang ^a,d   Lu, Pengcheng ^a,d   Johnson, J Chad ^a   Schmidt, Carl ^a   Bailey, Christina E ^a   Eschrich, Steven ^e   Kis, Christian ^a   Levy, Shawn ^a   Washington, M Kay ^a,d   Heslin, Martin J ^f   Coffey, Robert J ^a,d,g   Yeatman, Timothy J ^e   Shyr, Yu ^a,d   Beauchamp, R Daniel ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Colon Cancer Prognosis; Gene Expression Profiling; Mouse Model; Predictive Gene Signature

Indexed keywords

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FUNCTIONAL GENOMICS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL;

EID: 77249143960     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.11.005     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Ragnhammar P., Hafstrom L., Nygren P., and Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40 (2001) 282-308
3. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
4. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004) 1797-1806
5. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 (1999) 1349-1355
6. Quasar Collaborative Group, Gray R., Barnwell J., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (2007) 2020-2029
7. Figueredo A., Coombes M.E., and Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev (2008) CD005390
8. Figueredo A., Charette M.L., Maroun J., Brouwers M.C., and Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 (2004) 3395-3407
9. Lafreniere R., and Rosenberg S.A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 76 (1986) 309-322
10. Poste G., Doll J., and Fidler I.J. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A 78 (1981) 6226-6230
11. Fidler I.J., and Nicolson G.L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57 (1976) 1199-1202
12. Wu J.C., Sundaresan G., Iyer M., and Gambhir S.S. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther 4 (2001) 297-306
13. Jenkins D.E., Oei Y., Hornig Y.S., et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20 (2003) 733-744
14. Whitehead R.H. The culture of tumour cells from human tumour biopsies. Clin Oncol 2 (1976) 131-140
15. Smyth G.K., Michaud J., and Scott H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21 (2005) 2067-2075
16. Lee J.S., and Thorgeirsson S.S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127 suppl (2004) S51-S55
17. Tukey J.W. Tightening the clinical trial. Control Clin Trials 14 (1993) 266-285
18. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (2001) 539-548
19. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
20. Yanagisawa K., Shyr Y., Xu B.J., et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362 (2003) 433-439
21. Harrell Jr. F.E., Califf R.M., Pryor D.B., Lee K.L., and Rosati R.A. Evaluating the yield of medical tests. JAMA 247 (1982) 2543-2546
22. Barrier A., Boelle P.Y., Roser F., et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24 (2006) 4685-4691
23. Shedden K., Taylor J.M., Enkemann S.A., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14 (2008) 822-827
24. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
25. Hoshida Y., Villanueva A., Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
26. Wang Y., Jatkoe T., Zhang Y., et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22 (2004) 1564-1571
27. Lin Y.H., Friederichs J., Black M.A., et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 13 (2007) 498-507
28. Eschrich S., Yang I., Bloom G., et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23 (2005) 3526-3535
29. Garman K.S., Acharya C.R., Edelman E., et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A 105 (2008) 19432-19437
30. Wang D., and DuBois R.N. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 267 (2008) 197-203
31. Cooper H.S., Murthy S., Kido K., Yoshitake H., and Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 21 (2000) 757-768
32. Kado S., Uchida K., Funabashi H., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001) 2395-2398
33. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2 (2004) E7
34. Lee J.S., Chu I.S., Mikaelyan A., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36 (2004) 1306-1311
35. Kaposi-Novak P., Lee J.S., Gomez-Quiroz L., Coulouarn C., Factor V.M., and Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116 (2006) 1582-1595